

1 RESEARCH ARTICLE

2

3 Association between the *ACEI/D* gene polymorphism and progressive
4 renal failure in autosomal dominant polycystic kidney disease: A meta-
5 analysis

6

7

8 Noel Pabalan^{1*}, Phuntila Tharabenjasin¹, Yardnapar Parcharoen¹, Adis Tasanarong^{1, 2}

9

10

11 ¹ Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand

12

13 ² Nephrology Unit, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand

14

15

16

17

18

19

* noelpabalan@mail.com

20

21

22

Short title: Meta-analysis *ACE I/D* polymorphism progressive renal failure ADPKD

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

List of abbreviations

46		
47	ABP	Australia Bulgaria Poland
48	ACE	angiotensin converting enzyme gene
49	ACE	angiotensin converting enzyme protein
50	ADPKD	autosomal dominant polycystic kidney disease
51	AM	analysis model
52	BF	Bayes Factor
53	BFR	Belgium France
54	CB	Clark-Baudouin
55	CC	case-control
56	CI	confidence interval
57	CO	cohort
58	CS	cross-sectional
59	D	decreased risk
60	DD	variant homozygous genotype
61	DNA	deoxyribonucleic acid
62	EH	eliminated heterogeneity
63	ES	elevated significance
64	F	fixed-effects
65	GS	gained significance
66	HWE	Hardy-Weinberg Equilibrium
67	I	increased risk
68	I ²	measure of variability
69	I/D	polymorphism
70	ID	heterozygous genotype
71	II	common homozygous genotype
72	LS	lost significance
73	maf	minor allele frequency
74	mRNA	messenger ribonucleic acid
75	N	total number of comparisons
76	n	number of studies
77	<i>n</i>	frequency of occurrence
78	OR	odds ratio
79	P ^a	P-value for association
80	P ^b	P-value for heterogeneity
81	PRF	progressive renal failure
82	PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
83	PRO	pre-outlier
84	PSO	post-outlier
85	R	random-effects
86	[R]	Reference of studies
87	RNS	retained non-significance
88	RH	reduced heterogeneity
89	UKA	United Kingdom Australia
90	USA	United States of America
91		
92		
93		
94		
95		
96		
97		
98		
99		
100		

101 Abstract

102

103 **Objective** The *angiotensin converting enzyme* insertion/deletion (*ACE I/D*) gene
104 polymorphism is involved in a wide range of clinical outcomes. This makes *ACE I/D* an
105 important genetic marker. Updating the genetic profile of *ACE I/D* and raising the evidence
106 for its role in renal disease is therefore needed. Reported associations of *ACE I/D* with
107 progressive renal failure (PRF) in autosomal dominant polycystic kidney disease (ADPKD)
108 have been inconsistent, prompting a meta-analysis to obtain more precise estimates.

109 **Methods** Multi-database search yielded 18 articles for inclusion in the meta-analysis. Risks
110 (odds ratios [ORs] and 95% confidence intervals) were estimated by comparing the *ACE*
111 genotypes (heterozygote ID, homozygotes DD and II). Heterogeneous (random-effects)
112 pooled associations were subjected to outlier treatment which yielded fixed-effects outcomes
113 and split the findings into pre- (PRO) and post- (PSO) outlier status. Subgroup analysis was
114 based on ethnicity (Asian/Caucasian) and minor allele frequency (maf). The ≥ 0.50 maf
115 subgroup indicates higher frequency of the variant II genotype over that of the common DD
116 genotype, otherwise, the subgroup is considered < 0.50 maf. Stability of the associative
117 effects was assessed with sensitivity treatment. Temporal trend of association was examined
118 with cumulative meta-analysis.

119 **Results** In the PSO analysis, overall effects were null (ORs 0.99-1.02) but not in the
120 subgroups (Asian and ≥ 0.50 maf), where in presence of the D allele (DD/ID) and the I allele
121 (II), increased (ORs 1.63-5.62) and reduced (OR 0.22) risks were observed, respectively.
122 Of these pooled effects, the Asian and ≥ 0.50 maf homozygous DD genotypes had high ORs
123 (5.01-5.63) indicating elevated magnitude of effects that were highly significant ($P^a < 10^{-5}$)
124 and homogeneous ($I^2 = 0\%$), in addition to their robustness. In contrast, the Caucasian and
125 < 0.50 maf subgroup effects were: (i) non-heterogeneous (fixed-effects) at the outset, which
126 did not require outlier treatment and (ii) non-significant (ORs 0.91-1.10, $P^a = 0.15-0.79$).
127 Cumulative meta-analysis revealed increased precision of effects over time.

128 **Conclusions** PRF in ADPKD impacted the Asian and ≥ 0.50 maf subgroups where DD
129 homozygote carriers were up to 6-fold susceptible. The high magnitude of these effects
130 were highly significant, homogeneous and robust indicating strong evidence of association.

131

132 **Keywords:** *ACE*, I/D polymorphism, progressive renal failure, ADPKD, meta-analysis

133

134

135

136 Introduction

137
138 Autosomal dominant polycystic kidney disease (ADPKD) is an inherited systemic disease
139 characterized by fluid filled cysts in the kidneys leading to end stage renal failure in later
140 years of life [1]. Preventing progressive renal failure (PRF) is mainly treated with controlling
141 blood pressure and reducing proteinuria [2]. However, these reno-protective measures do not
142 benefit all patients [3]. These differential treatment outcomes may in part be attributed to
143 genetics. Studies on mouse and human models suggest that genetic variation plays a
144 significant role in PRF associated with ADPKD [4,5]. One genetic variation is the insertion/
145 deletion (I/D) polymorphism in the *angiotensin converting enzyme (ACE)* gene, a 24 kb
146 sequence of DNA in intron 16 of chromosome 17q23. This gene encodes the ACE protein,
147 which is found in mammalian tissues and body fluids as ectoenzymes on cell surfaces and in
148 serum [6]. The I/D polymorphism has been shown to determine the levels of circulating ACE
149 enzymes [7]. ACE enzyme levels have been suggested to associate with the *ACE* genotypes
150 (heterozygote ID, homozygotes DD and II) possibly affecting therapeutic response [8].
151 Individuals carrying the DD homozygote genotype were found to exhibit the highest serum
152 ACE activity when compared to carriers of II homozygote and ID heterozygote genotype
153 who showed low and intermediate activity, respectively [7]. The relationship between ACE
154 activity and *ACE* genotypes, specifically homozygous DD appears to be the central concept
155 in the clinical genetics of renal disease [9]. In a modification of ACE activity, a meta-analysis
156 of 46 studies revealed that the genotypes (ID, DD) containing the D allele showed higher
157 plasma ACE activity than the homozygous II genotype [10]. In ADPKD patients, the DD
158 homozygote genotype was found to correlate with progression of renal insufficiency [11]. In
159 addition, ADPKD patients have hypertension, a severe complication in which the *ACE* gene
160 is most likely involved [10]. The value of *ACE* I/D as a genetic marker lies in its association
161 with risk of a wide range of clinical outcomes that include response to ACE inhibitor therapy

162 [12], cardiovascular diseases [10], diabetes-related [13,14], cancer [15], longevity [16],
163 Alzheimer's disease [17] and muscle performance [18]. The span of *ACE* involvement in a
164 wide variety of clinical conditions and evidence of elevated ACE activity associated with the
165 *ACE* D allele prompted a Genome-Wide Association Study (GWAS) from the quantitative
166 trait loci perspective [19], with no mention of ADPKD. Another GWAS profiled ADPKD
167 from an epigenetic perspective [20], with no mention of *ACE* I/D. Thus, GWAS has involved
168 *ACE* I/D and ADPKD which were not reported in the same study. One study that examined
169 both *ACE* I/D and ADPKD was a meta-analysis, which was published in 2006 [21]. Since
170 then, new primary studies have emerged, with inconsistent results. Given the variability of
171 results and length of time (13 years) since the last synthesis, we undertook this meta-analysis
172 for three reasons: (i) obtain less ambiguous, clearer estimates and updated role of *ACE* I/D
173 with renal failure progression in ADPKD; (ii) apply novel meta-analysis techniques (e.g.
174 outlier treatment) in order to raise the strength of evidence and (iii) examine the cumulative
175 trend of association. Simultaneous application of meta-analysis treatments that focus on the
176 pathophysiological role of *ACE* I/D precluded inclusion of other polymorphisms in this study.
177 This meta-analysis aims for better understanding of the genetics of PRF in ADPKD, so that it
178 may provide important information that might be useful to decision makers in healthcare,
179 particularly in the field of nephrology.

180

181 **Materials and Methods**

182

183 **Selection of studies**

184

185 Two authors (NP and PT) performed primary screening (titles/abstracts) and disagreements
186 were resolved through screening of the title/abstract in question by a third author (YP). Three
187 databases (PubMed in MEDLINE, Google Scholar and Science Direct) were searched for

188 association studies as of March 12, 2019. Terms used were “*angiotensin converting enzyme*”,
189 “*ACE*”, “*ADPKD*”, “autosomal dominant polycystic kidney disease” and “polymorphism” as
190 medical subject heading and text, restricted to the English language. Additional eligible
191 studies were identified from references cited in the retrieved articles. Inclusion criteria were:
192 (i) case–control study design evaluating the association between *ACE* I/D and PRF in
193 *ADPKD* and (ii) sufficient genotype or allele frequency data to allow calculation of odds
194 ratios (ORs) and 95% confidence intervals (CIs). Exclusion criteria are: (i) studies without
195 controls or studies whose genotype or allele frequencies were unusable/absent; (ii) those that
196 did not cover the polymorphism or disease in question, (iii) reviews and (iv) non-English
197 articles ([S1 List](#)).

198 **S1 List** Excluded studies

199 Data extraction

200 Two investigators independently extracted the data that resulted in consensus. Extracted
201 information from each article included the first author’s name, publication year, country of
202 origin, ethnicity, study design and whether the articles addressed the Hardy-Weinberg
203 Equilibrium (HWE). Articles which were not included in a previous meta-analysis [21] are
204 indicated by an asterisk under the author column ([Table 1](#)). Primary study authors were
205 contacted in order to obtain more information on incomplete data. Less than a third of the
206 included studies mentioned influence of the environment, but data were not provided.

207 Data distribution, power calculations and HWE assessment

208 Data distribution was assessed with the Shapiro-Wilks (SW) test using SPSS 20.0 (IBM
209 Corp., Armonk, NY, USA). Normal distribution ($P > 0.05$) warranted descriptive and
210 inferential expressions of mean \pm standard deviation (SD) and the parametric approach,
211 respectively. Otherwise, the median (with interquartile range) and non-parametric tests were
212 used, respectively. Using the G*Power program [22], we evaluated statistical power as its

213 adequacy bolsters the level of associative evidence. Assuming an OR of 1.5 at a genotypic
214 risk level of $\alpha = 0.05$ (two-sided), power was considered adequate at $\geq 80\%$. HWE was
215 assessed using the application in <https://ihg.gsf.de/cgi-bin/hw/hwa1.pl>.

216 Methodological quality of the studies

217
218 We used the Clark-Baudouin (CB) scale to evaluate methodological quality of the included
219 studies [23]. The CB criteria include P-values, statistical power, correction for multiplicity,
220 comparative sample sizes between cases and controls, genotyping methods and the HWE. In
221 this scale, low, moderate and high have scores of < 5 , 5-6 and ≥ 7 , respectively.

222 Genetic models

223 From the 18 included studies [24-41], minor allele frequency (maf) of the homozygous II
224 genotype among controls was < 0.50 in 11 of them [25,30-33,35-37,39-41] and not (≥ 0.50)
225 the remaining seven [24,26-29,34,38]. Non-uniformity of the maf across the studies (S1
226 Table) influenced our study design in two ways: (1) maf data were dichotomized into
227 ≥ 0.50 maf (DD $<$ II) and < 0.50 maf (DD $>$ II) and (2) precluded the use of standard genetic
228 modeling. Thus, we opted for the allele-genotype model, wherein we compared (i) DD
229 homozygotes with the ID/II genotype; (ii) II homozygotes with ID/DD genotype and
230 (iii) heterozygous ID genotype carriers with homozygotes of the II and DD genotypes.

231 S1 Table Quantitative features of the included studies

232

233 Data synthesis

234

235 Risks of PRF in ADPKD (using raw data for frequencies) were estimated for each study and
236 comparing the effects on the same baseline, we calculated pooled ORs. We performed a
237 cumulative meta-analysis to examine changes in the pooled ORs with accumulation of data
238 over time. Subgrouping was ethnicity-based (Asians and Caucasians) and maf-based (≥ 0.50
239 maf and < 0.50 maf). To assess the strength of evidence, we used three indicators: First, the

240 magnitude of effects are higher or lower when the pooled ORs are farther from or closer to
241 the OR value of 1.0 (null effect), respectively [42]. Second, the P-value is contextualized
242 from the Bayesian perspective of the Bayes Factor (BF). The BF compares support from the
243 null and alternate hypotheses, in contrast to the P-value, which addresses the null only [43].
244 Thus, P-values (Z-scores) of 0.05 and 0.001 (corresponding to minimum BFs of ≥ 0.15 and
245 0.005) indicate moderate and strong (to very strong) evidence, respectively [44]. The BF rests
246 on the likelihood paradigm [45], indicative of how strong the hypotheses are supported by the
247 data [43]. Thus, the likelihoods between the absence (null hypothesis) and presence (alternate
248 hypothesis) of association of *ACE I/D* with PRF in ADPKD are compared. Third,
249 homogeneity is preferred to heterogeneity, but heterogeneity is unavoidable [46]. Thus,
250 occurrence of heterogeneity between studies was estimated with the χ^2 -based Q test [47],
251 with threshold of significance set at $P^b < 0.10$. Heterogeneity was also quantified with the I^2
252 statistic which measures variability between studies [48]. I^2 values of $> 50\%$ indicate more
253 variability than those $\leq 50\%$ with 0% indicating zero heterogeneity (homogeneity). Evidence
254 of functional similarities in population features of the studies warranted using the fixed-
255 effects model [49], otherwise the random-effects model [50] was used. Sources of
256 heterogeneity were detected with the Galbraith plot [51] followed by re-analysis (outlier
257 treatment). Of note, outlier treatment dichotomized the comparisons into pre-outlier (PRO)
258 and post-outlier (PSO). Sensitivity analysis, which involves omitting one study at a time and
259 recalculating the pooled OR, was used to test for robustness of the summary effects. We
260 assessed publication bias for comparisons that met two conditions: (i) ≥ 10 studies only [52]
261 and (ii) significant outcomes. Except for heterogeneity estimation [47], two-sided P-values of
262 ≤ 0.05 were considered significant. All associative outcomes were Bonferroni-corrected in
263 order to control for Type 1 error. Data for the meta-analysis were analyzed using Review

264 Manager 5.3 (Cochrane Collaboration, Oxford, England), SIGMASTAT 2.03, and SIGMAPLOT
265 11.0 (Systat Software, San Jose, CA).

266

267 **Results**

268

269 **Search results and study features**

270

271 [Figure 1](#) outlines the study selection process in a PRISMA-sanctioned flowchart (Preferred
272 Reporting Items for Systematic Reviews and Meta-Analyses). Initial search resulted in 548
273 citations, followed by a series of omissions ([S1 List](#)) that eventually yielded 18 articles for
274 inclusion [[24-41](#)].

275

276 **Fig 1** Summary flow chart of literature search

277

278 **S1 List** Excluded studies

279

280

281 **Characteristics of the included studies**

282

283 [Table 1](#) shows that the number of Caucasian (n = 12) studies was twice that of the Asians (n
284 = 6). Methodological quality of the component studies was moderate based on mean and SD
285 (6.37 ± 1.24) of the normally distributed CB scores (SW test: $P = 0.33$). [S1 Table](#) shows the
286 quantitative features of the included studies, specifically the differential frequencies of the
287 *ACE* genotypes between the race subgroups, where II was higher (83%: 5/6) in the Asian
288 studies and lower (17%: 2/12) in the Caucasian studies. Adequate statistical power was
289 absent in the Asian studies, and present in two Caucasian studies [[31,34](#)]. At the aggregate
290 level, however, power in both ethnic subgroups was > 80% (Asian: 97.3%; Caucasian:
291 100.0%). Control frequencies deviated from the HWE in four studies [[27,28,36,41](#)]. This
292 meta-analysis followed the PRISMA and genetic association guidelines ([S2-S3 Tables](#)).

293

294

295 **S1 Table** Quantitative features of the included studies

296

297 **S2 Table** PRISMA checklist

298

299 **S3 Table** Meta-analysis checklist

300

301

302 **Table 1** Characteristics of the included studies that examined *ACE I/D* polymorphism
 303 associations with PRF in ADPKD

304

	First author	[R]	Year	Country	Ethnicity	Study design	Addressed HWE	CB
1	Konoshita	[24]	2001	Japan	Asian	CS	Yes	7
2	Lee	[25]	2000	Korea	Asian	CS	NM	5
3	Ramanathan *	[26]	2016	India	Asian	CC	Yes	6
4	Tripathi	[27]	2006	India	Asian	CC**	NM	7
5	Tripathi *	[28]	2008	India	Asian	CC**	NM	8
6	Uemasu	[29]	1997	Japan	Asian	CC	NM	5
7	Baboolal	[30]	1997	UKA	Caucasian ^a	CS	Yes	7
8	Buraczynska *	[31]	2006	Poland	Caucasian	CC**	Yes	7
9	Ecdar	[32]	2003	USA	Caucasian	CS	Yes	8
10	Gumprecht *	[33]	2007	Poland	Caucasian	CS	NM	4
11	Lovati *	[34]	2001	Switzerland	Caucasian ^a	CC**	Yes	9
12	Merta	[35]	2003	Czechoslovakia	Caucasian	CC	Yes	5
13	Perez-Oller	[36]	1999	Spain-	Caucasian	CS	NM	6
14	Persu	[37]	2003	BFR	Caucasian	CS	Yes	6
15	Saggar-Malik	[38]	2000	UK	Caucasian	CO	NM	6
16	Schiavello	[39]	2001	ABP	Caucasian	CS	Yes	6
17	van Dijk *	[40]	2000	Netherlands	Caucasian	CC**	Yes	6
18	Wanic-Kossowska *	[41]	2014	Poland	Caucasian	CC**	NM	7

305

306

307

308

309

ACE: angiotensin converting enzyme gene; *I/D*: polymorphism; PRF: progressive renal failure; ADPKD: autosomal dominant polycystic kidney disease; [R]: reference number of the studies; UKA: United Kingdom Australia; USA: United States of America; BFR: Belgium France; ABP: Australia Bulgaria Poland; CS: cross-sectional; CC: case-control; CO: cohort; ** diluted cases (ADPKD was one of the disease conditions of the patients); HWE: Hardy-Weinberg Equilibrium; NM: not mentioned; CB: Clark-Baudouin; *not in the Pereira (2006) meta-analysis; Caucasian ^a: admixed population

310

311

312

313

314

315

316

317

318 Meta-analysis outcomes

319

320 The overall PRO homozygote DD genotype outcome indicating increased risk (OR 1.37)
321 was marginally significant ($P^a = 0.05$) and nullified in the PSO analysis (OR 1.02, $P^a = 0.78$).
322 HWE analysis validated the overall outcomes (Table 2). In the subgroups (Table 3), seven
323 associative outcomes (Asian and ≥ 0.50 maf) were statistically significant, moderate in PRO
324 ($P^a = 0.01-0.02$) and high in PSO ($P^a < 10^{-4}$ to 10^{-5}). The PSO outcomes survived the
325 Bonferroni-correction, but the PRO did not. The highly significant PSO outcomes had the
326 following features: (i) all were homogeneous ($I^2 = 0\%$); (ii) magnitude of the homozygote
327 DD increased risk effects was more (ORs 5.01-5.62) than that in heterozygote ID (ORs 1.63-
328 1.68); and (iii) the pooled homozygote II effect indicated reduced risk (OR 0.22). In contrast,
329 Caucasian and < 0.50 maf outcomes were non-associative between ACE I/D and PRF in
330 ADPKD (ORs 0.91-1.10, 95% CI 0.79-1.31, $P^a = 0.15-0.79$), and initially non-heterogeneous
331 (fixed-effects) which precluded outlier treatment (Table 3).

332 **Table 2** Overall and modified outcomes of ACE I/D effects on PRF in ADPKD
 333

	Test of association								Test of heterogeneity								Effect of outlier treatment	
	n	OR	95% CI	P ^a	Risk	P ^b	I ² (%)	AM	n	OR	95% CI	P ^a	Risk	P ^b	I ² (%)	AM	Significance	Heterogeneity
	PRO								PSO									
Overall																		
DD	18	1.37	1.00-1.88	0.05*	I	10 ⁻⁵	82	R	15	1.02	0.90-1.16	0.78	Null	0.27	0	F	LS	EH
ID	18	0.96	0.78-1.19	0.70	D	10 ⁻⁵	89	R	15	1.01	0.88-1.15	0.91	Null	0.24	19	F	RNS	RH
II	18	0.83	0.59-1.18	0.30	D	10 ⁻⁵	84	R	13	0.99	0.85-1.16	0.95	Null	0.15	29	F	RNS	RH
HWE																		
DD	14	1.14	0.91-1.42	0.27	I	0.01	53	R	12	0.99	0.84-1.16	0.87	Null	0.27	18	F	RNS	RH
ID	14	0.96	0.86-1.08	0.51	D	0.11	34	F	---	---	---	---	---	---	---	---	---	---
II	14	0.83	0.63-1.08	0.17	D	0.0009	63	R	13	1.00	0.87-1.15	0.95	Null	0.20	24	F	RNS	RH

334 ACE: angiotensin converting enzyme gene; I/D: polymorphism; PRF: progressive renal failure; ADPKD: autosomal dominant polycystic kidney disease; DD
 335 and II: homozygote genotypes; ID: heterozygote genotype; HWE: Hardy-Weinberg Equilibrium; n: number of studies; OR: odds ratio; CI: confidence interval;
 336 P^a: P-value for association; I: increased risk; D: decreased risk; Null ORs = 0.97-1.03; P^b: P-value for heterogeneity; I²: measure of variability; AM: analysis
 337 model; R: random-effects; F: fixed-effects; PRO: pre-outlier; PSO: post outlier; LS: lost significance; RNS: retained non-significance; EH: eliminated
 338 heterogeneity; RH: reduced heterogeneity; values in bold indicate significant associations; *did not survive the Bonferroni correction
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349

350
351
352

Table 3 Subgroup effects of the *ACE* I/D polymorphism on PRF in ADPKD

	Test of association				Test of heterogeneity				Test of association				Test of heterogeneity				Effect of outlier treatment	
	n	OR	95% CI	P ^a	Risk	P ^b	I ² (%)	AM	n	OR	95% CI	P ^a	Risk	P ^b	I ² (%)	AM	Significance	Heterogeneity
	PRO								PSO									
Asian																		
DD	6	2.84	1.25-6.44	0.01*	I	10 ⁻⁴	83	R	4	5.62	3.93-8.04	10⁻⁵	I	0.96	0	F	ES	EH
ID	6	1.13	0.58-2.20	0.73	I	10 ⁻⁵	87	R	5	1.63	1.27-2.10	10⁻⁴	I	0.61	0	F	GS	EH
II	6	0.48	0.22-1.04	0.06	D	10 ⁻⁵	89	R	3	0.22	0.16-0.29	10⁻⁵	D	0.44	0	F	GS	EH
Caucasian																		
DD	12	1.02	0.89-1.16	0.79	Null	0.18	27	F	---	---	---	---	---	---	---	---	---	---
ID	12	0.92	0.81-1.03	0.15	D	0.22	23	F	---	---	---	---	---	---	---	---	---	---
II	12	1.09	0.95-1.26	0.23	I	0.24	21	F	---	---	---	---	---	---	---	---	---	---
≥ 0.50 maf (DD < II)																		
DD	7	2.73	1.21-6.18	0.02*	I	10 ⁻⁵	91	R	5	5.01	3.60-6.96	10⁻⁵	I	0.49	0	F	ES	EH
ID	7	1.01	0.62-1.64	0.97	Null	10 ⁻⁵	85	R	4	1.68	1.29-2.18	10⁻⁴	I	0.54	0	F	GS	EH
II	7	0.52	0.26-1.04	0.07	D	10 ⁻⁵	92	R	4	1.05	0.85-1.29	0.65	I	0.27	23	F	RNS	RH
< 0.50 maf (DD > II)																		
DD	11	1.03	0.88-1.19	0.73	Null	0.35	10	F	---	---	---	---	---	---	---	---	---	---
ID	11	0.91	0.79-1.04	0.17	D	0.22	23	F	---	---	---	---	---	---	---	---	---	---
II	11	1.10	0.92-1.31	0.28	I	0.21	25	F	---	---	---	---	---	---	---	---	---	---

353 *ACE*: angiotensin converting enzyme gene; I/D: polymorphism; PRF: progressive renal failure; ADPKD: autosomal dominant polycystic kidney disease; DD and II: homozygote
354 genotypes; ID: heterozygote genotype; maf: minor allele frequency; n: number of studies; OR: odds ratio; CI: confidence interval; P^a: P-value for association; I: increased risk;
355 D: decreased risk; Null: ORs = 0.97-1.03; P^b: P-value for heterogeneity; I²: measure of variability; AM: analysis model; R: random-effects; F: fixed-effects; PRO: pre-outlier;
356 PSO: post outlier; ES: elevated significance; GS: gained significance; RNS: retained non-significance; EH: eliminated heterogeneity; RH: reduced heterogeneity; values in bold
357 indicate significant associations; * did not survive the Bonferroni correction

358 Mechanism and impact of outlier treatment

359

360 The mechanism of outlier treatment for the homozygous DD genotype in the Asian subgroup
361 is visualized in Figs 2-4. Fig 2 shows the PRO forest plot, moderately significant (OR 2.84,
362 95% CI 1.25-6.44, $P^a = 0.01$) and heterogeneous ($P^b < 10^{-4}$, $I^2 = 83\%$). The Galbraith plot
363 identifies two studies [25,26] as the sources of heterogeneity (outliers), located below the -2
364 confidence limit (Fig 3). In Fig 4, the PSO outcome (outliers omitted) shows eliminated
365 heterogeneity ($P^b = 0.96$, $I^2 = 0\%$); intensified increased risk effect (OR 5.62, 95% CI 3.93-
366 8.04) and escalated significance ($P^a < 10^{-5}$). This operation is numerically summarized in
367 Table 2.

368

369 **Fig 2** Forest plot outcome of the Asian *ACE* homozygous DD effects on PRF in
370 ADPKD

371

372 **Fig 3** Galbraith plot analysis for the *ACE* homozygous DD genotype in the Asian
373 subgroup

374

375 **Fig 4** Forest plot outcome of outlier treatment on the Asian *ACE* homozygous DD
376 effects on PRF in ADPKD

377

378

379 Sensitivity analysis and publication bias

380

381 The high magnitude (ORs 5.01-5.62) of the homozygote DD Asian and ≥ 0.50 maf effects
382 were robust, but not the heterozygote ID and homozygote II genotypes (Table 4). In the DD
383 homozygote genotype, the Asian effects were more robust than the ≥ 0.50 maf subgroup
384 (Table 4). Thus, the Asian DD effects were more stable than that in ≥ 0.50 maf.

385

386 Only the PRO overall analysis for the homozygous DD genotype was eligible for
387 publication bias assessment. Non-normal distribution (SW test: $P < 10^{-4}$) of its operating data
388 (ORs) prompted the use of Begg-Mazumdar test of correlation [53] which showed no
389 evidence of publication bias (Kendall's $\tau = 0.23$, $P = 0.19$).

389

390

391 **Table 4** Sensitivity analysis of significant *ACE* I/D ADPKD outcomes

392

Comparison	Geno- type	PRO	PSO	A	B
Overall	DD	Robust	Robust	0	2
Asian	DD	Robust	Robust	0	2
Asian	ID	-----	[28]	1	0
Asian	II	-----	[24,26]	2	0
≥ 0.50 maf	DD	[27,29,38]	Robust	3	1
≥ 0.50 maf	ID	-----	[28]	0	1
A		3	4		
B		2	3		

393 *ACE*: angiotensin converting enzyme gene; I/D: polymorphism; ADPKD:
 394 autosomal dominant polycystic kidney disease; maf: minor allele frequency;
 395 DD and II: homozygote genotypes; ID: heterozygote genotype; A: Number
 396 of references contributing to non-robustness; numbers in brackets indicate
 397 references that contributed to non-robustness; B: Number of robust outcomes;
 398 PRO: pre-outlier; PSO: post-outlier

399

400 Cumulative meta-analysis

401

402 [Fig 5](#) outlines the trend of pooled effects from 1997 to 2016. Here, the “decline effect” is

403 apparent where initial studies show the early extreme phenomenon [54] compared with the

404 subsequent and modulated pooled ORs. Significance was observed in the early studies (1997-

405 1999), lost in the subsequent ones (2000-2006), and then regained in the recent studies (2008-

406 2016). A trend of increasing precision (narrowing of the CIs) is readily observed in the graph.

407

408 **Fig 5** Cumulative meta-analysis of the associations between the *ACE* homozygous
 409 DD genotype and PRF in ADPKD

410

411

412 Discussion

413

414 Summary of associations

415

416 Evidence of association between the *ACE* homozygous DD genotype and risk of PRF in

417 ADPKD is tenuous in the overall analysis but strong in the subgroups (Asian and ≥ 0.50) at

418 the PSO level. This strength rests on the three indicators: (i) high magnitude of effects (up to

419 5.6-fold), which were (ii) homogeneous (indicating combinability of the studies) and (iii)
420 highly significant (up to $P^a < 10^{-5}$). Of note in the Asian subgroup, the II homozygous effect
421 indicating 78% reduced risk also met the high strength of evidence criteria (Table 3), but was
422 found to be non-robust, which contrasted with robustness of the homozygous DD effect. Our
423 use of subgroup analysis and outlier treatment have unraveled significant and homogeneous
424 associations in three contexts, (i) not achieved in a previous meta-analysis; (ii) neither present
425 in the overall analysis; (iii) nor in the component single-study outcomes. However, the
426 process of subgrouping and performing outlier treatment reduced the number of studies and
427 sample sizes of the comparisons. These may decreased statistical power and risked Type 1
428 error, especially in light of a few (three to five) PSO studies generating multiple significant
429 outcomes in the subgroup analyses. Fortunately, adequate statistical powers of the three to
430 five Asian studies (82.2-97.3%) and their P-values surviving the Bonferroni correction served
431 to minimize the possibility of false-positives and increase confidence in the outcomes. Non-
432 associative outcomes in previous primary studies may be attributed to their lack of power and
433 small sample sizes. Underpowered outcomes appear to be common in candidate gene studies
434 [55] and are prone to the risk of Type 1 error. Other highlights of our findings are differential
435 effects between the ethnic (Asian versus Caucasian) and maf (≥ 0.50 versus < 0.50)
436 subgroups. Significant outcomes in Asian but not in Caucasians may be attributed to
437 differences in maf between the two ethnicities [56].

438 Cumulative meta-analysis

439 Studies on associations between ACE I/D and PRF in ADPKD from the last 20 years
440 produced outcomes that reduced the magnitude and retained the heterogeneity of
441 associations. On the other hand, the sustained increased precision and cumulative
442 significance of effects as well as increase in the number of studies may help establish
443 evidence of association.

444 Comparison with other meta-analyses

445 Five previous meta-analyses relate to our study, four of them not as direct as the fifth. The
446 first [57] focused on angiotensin II types 1 and 2 receptor genes (*AGTR1* and *AGTR2*) in
447 various renal diseases that did not include ADPKD. The second to the fourth meta-analyses
448 [13,14,58] focused on *ACE* I/D with the outcome of end-stage renal disease (ESRD). All
449 three demonstrated associations of *ACE* I/D with ESRD, two of which drew race-specific
450 conclusions, one for Caucasians [58] and the other for Asians [14]. The fifth [21] directly
451 relates to our study which was published 13 years ago (2006); the features of both are
452 outlined in Table 4. Pereira et al [21] included non-English articles and meeting abstracts,
453 which we did not in our study because we evaluated methodological quality of the included
454 studies. Methodology-wise, Pereira et al used the recessive model (homozygous DD versus
455 heterozygous ID + homozygous II genotypes) versus the genotype model (homozygous DD,
456 and II, heterozygous ID) in ours. Comparative outcomes are based on the homozygous DD
457 genotype (Table 5). Three differences mark the overall analyses (ours and the previous): (i)
458 the number of studies (18 versus eight); (ii) significance of outcome ($P^a = 0.05$ versus $P =$
459 0.21) and (iii) magnitude of outcome (1.4-fold versus 1.2-fold). In the racial subgroups,
460 Pereira et al showed no material differences between the Asian and Caucasian outcomes
461 (both indicated non-significant increased risks, randomly-derived). In contrast, our outcomes
462 differentiated between the Asians and Caucasians (up to 6-fold versus null). In the Asian
463 outcomes, ours and the previous differed in terms of: (i) significance ($P^a = 0.01-10^{-4}$ versus P
464 $= 0.23$) and magnitude of effect (up to 5.6-fold versus 1.6-fold). In the Caucasian analyses,
465 ours versus previous differed in the number of studies (12 versus four) and outcomes (null
466 versus 1.2-fold).

467

468

469

470 **Table 4** Comparison of features between the two meta-analyses

471

	This study	Pereira et al [21]
General features		
Year	2019	2006
Country	Thailand	Brazil
Subgroups	Race/minor allele frequency	Race
Genetic modeling	Allele/Genotype	Recessive
Methods / Treatments		
HWE as inclusion criterion	Yes	No
Modifier analysis	Yes	No
Outlier analysis	Yes	No
Heterogeneity	Q statistic, I^2	Q statistic
Sensitivity analysis	Yes	No
Publication bias	Yes	Yes

472 HWE: Hardy-Weinberg Equilibrium

473 **Table 5** Comparison of outcomes between the current meta-analysis and the 2006 meta-analysis

Comparison		This study							Pereira et al [21]						
		Homozygous DD genotype							Homozygous DD versus heterozygous ID + homozygous II genotypes						
		n	OR	95% CI	P ^a	Effect	P ^b	AM	n	OR	95% CI	P ^a	Effect	P ^b	AM
All	PRO	18	1.37	1.00-1.88	0.05*	I	10 ⁻⁵	R	8	1.23	0.89-1.80	0.21	I	0.29	R
	PSO	15	1.02	0.90-1.16	0.78	Null	0.27	F							
Asian	PRO	6	2.84	1.25-6.44	0.01*	I	10 ⁻⁴	R	4	1.56	0.75-3.24	0.23	I	0.79	R
	PSO	4	5.63	3.93-8.04	10⁻⁴	I	0.96	F							
Caucasian	-----	12	1.02	0.89-1.16	0.79	Null	0.18	F	4	1.17	0.76-1.80	0.47	I	0.09	R

474 ACE: *angiotensin converting enzyme* gene; I/D: polymorphism; DD and II: homozygote genotypes; ID: heterozygote genotype; PRO: pre-outlier;
 475 PSO: post-outlier; n: number of studies; OR: odds ratio; CI: confidence interval; P^a: P-value for association; I: increased risk; Null: ORs = 0.97-1.03;
 476 P^b: P-value for heterogeneity; AM: analysis model; R: random-effects; F: fixed-effects; values in bold indicate significant associations; *did not survive
 477 the Bonferroni correction

478 Genetic correlates

479

480 Understanding the impact of *ACE I/D* on renal disease might clarify the role of the

481 homozygous DD genotype in PRF and/or variable responses to renoprotective therapy.

482 Based on the evidence that the homozygous DD genotype elicits high ACE activity [7], it

483 was hypothesized that the homozygous DD genotype were resistant to renoprotective therapy

484 [9]. However, it has also been hypothesized that *ACE I/D* is in linkage disequilibrium with an

485 unknown DNA section containing a silencer motif that could inhibit ACE mRNA translation

486 [59,60]. This suggests variability of ACE expression at the DNA/mRNA level. Studies have

487 reported increased ACE mRNA expression in homozygous DD genotype patients in renal

488 [61] and other tissues [62,63]. It is then possible to identify different polymorphisms in the

489 *ACE* gene to identify patients at risk for PRF or therapy resistance. Evidence for the

490 association between serum ACE levels and ADPKD has not been consistent [33,39]. The

491 numerous studies that examined associations at the gene level had conflicting outcomes. An

492 association between the D allele of *ACE I/D* among ADPKD patients has been detected in

493 various populations [24,30,37,40], but not in others [25,29,32,33,35,36,39].

494

495 *ACE* gene, ACE protein and RAAS

496

497 The renin-angiotensin aldosterone system (RAAS) is critical in regulating blood pressure and

498 electrolyte balance [64,65]. The activity of RAAS system in turn, is regulated by the ACE

499 protein where it mediates the rate of production of angiotensinogen from renin [66]. RAAS is

500 activated in progressive kidney disease leading to hypertension [67]. The role of hypertension

501 in the progression of kidney deterioration in ADPKD places the *ACE I/D* polymorphism at

502 the core of this research. On a morphological level, the pathophysiology of ADPKD involves

503 RAAS where it directly stimulates the growth of renal cysts [68]. Angiotensin II, a RAAS

504 component was observed within cysts and tubules leading to the cyst expansion [69].

505 Strengths and limitations

506

507 Interpreting our findings should consider its limitations and strengths. Limitations include:

508 (i) Eighty-nine percent of the component studies were underpowered; (ii) of the 29
509 comparisons, 22 (76%) were heterogeneous; (iii) pathological conditions of the some cases
510 were diluted, where ADPKD comprised part of the patients' condition and (iv) despite the
511 high significance ($P^a < 10^{-5}$) and magnitude (5-fold) as well as homogeneity ($I^2 = 0\%$) of the
512 homozygous DD PSO pooled effects in the Asian and ≥ 0.50 maf comparisons, their wide
513 CIs (3.60-8.04), suggests imprecision which may have compromised the durability of effects.
514 Larger sample sizes may be needed to ameliorate this limitation [70]. Of note, precision in
515 this study had opposing effects, reduced (wide CIs) with subgroup treatment but increased
516 (narrow CIs) with cumulative meta-analysis. The methodology may explain this paradox in
517 terms of sample size and number of studies (n), which was reduced with subgroup analysis
518 but increased with cumulative meta-analysis.

519 On the other hand, the strengths comprise of the following: (i) the combined sample
520 sizes of the overall and subgroups translated to high statistical power; (ii) ten (56%) of the
521 18 articles addressed HWE concerns. Confining the analysis to studies in HWE did not
522 materially alter the pooled ORs; in fact, HWE-analysis validated the overall pooled effects.
523 Given this outcome, the risk of genotyping errors appears to be a minor issue which
524 minimizes methodological weakness in our study; (iii) outlier treatment reduced and
525 eliminated heterogeneity and enabled significance; (iv) the significant PSO ORs in the Asian
526 and ≥ 0.50 maf subgroups survived the Bonferroni correction, thus minimizing the possibility
527 of a Type 1 error; (v) sensitivity treatment conferred robustness to the overall and Asian
528 homozygous DD findings and (vi) publication bias was not evident in the PRO overall
529 comparison.

530

531 Conclusions

532

533 We have shown that associations of *ACE I/D* with PRF in ADPKD are genotype dependent.

534 Substantial amount of evidence presented here may render *ACE I/D* useful as prognostic

535 markers for PRF in ADPKD. In spite of the evidence for associations, the complexity of

536 ADPKD involves interactions between genetic and non-genetic factors allowing for the

537 possibility of environmental involvement. Gene-gene and gene-environment interactions

538 have been reported to have roles in associations of other polymorphisms with ADPKD. All

539 but five [\[29,32,38,39,41\]](#) of the 18 articles acknowledged gene-environment interaction.

540 Addressing gene-gene and gene-environment interactions [\[71\]](#) may help address the

541 pathophysiological significance of *ACE I/D* and PRF in ADPKD. Four of the included

542 articles mentioned haplotype analysis [\[26,27,35,39\]](#) with one presenting haplotype data [\[26\]](#).

543 Focus on *ACE* haplotypes have been suggested for future association studies [\[72\]](#). Additional

544 well-designed studies exploring other parameters would confirm or modify our results in this

545 study and add to the extant knowledge about the association of the *ACE* polymorphism and

546 PRF in ADPKD.

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

References

562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619

1. Sun Y, Zhou H, Yang BX (2011) Drug discovery for polycystic kidney disease. *Acta Pharmacol Sin* 32: 805-816.
2. Remuzzi G, Ruggenti P, Benigni A (1997) Understanding the nature of renal disease progression. *Kidney Int* 51: 2-15.
3. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, et al. (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. *Ann Intern Med* 139: 244-252.
4. Hoefele J, Mayer K, Scholz M, Klein HG (2011) Novel PKD1 and PKD2 mutations in autosomal dominant polycystic kidney disease (ADPKD). *Nephrol Dial Transplant* 26: 2181-2188.
5. Wu G, Tian X, Nishimura S, Markowitz GS, D'Agati V, et al. (2002) Trans-heterozygous Pkd1 and Pkd2 mutations modify expression of polycystic kidney disease. *Hum Mol Genet* 11: 1845-1854.
6. Villard E, Tiret L, Visvikis S, Rakotavoa R, Cambien F, et al. (1996) Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. *Am J Hum Genet* 58: 1268-1278.
7. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, et al. (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest* 86: 1343-1346.
8. Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, et al. (1998) Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. *Kidney Blood Press Res* 21: 66-69.
9. Kleij FGHVD (2002) Angiotensin-converting enzyme gene insertion/deletion polymorphism and renal disease. Groningen: University of Groningen.
10. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A (2000) ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. *Arterioscler Thromb Vasc Biol* 20: 484-492.
11. Osono E, Kurihara S, Hayama N, Sakurai Y, Ohwada K, et al. (1998) Insertion/deletion polymorphism in intron 16 of the ACE gene and left ventricular hypertrophy in patients with end-stage renal disease. *Am J Kidney Dis* 32: 725-730.
12. Scharplatz M, Puhan MA, Steurer J, Bachmann LM (2004) What is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors?--Protocol of a systematic review. *BMC Med Genet* 5: 23.
13. Yu ZY, Chen LS, Zhang LC, Zhou TB (2012) Meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy. *Nephrology (Carlton)* 17: 480-487.
14. Shen W, Jiang XX, Li YW, He Q (2019) I/D polymorphism of ACE and risk of diabetes-related end-stage renal disease: a systematic review and meta-analysis. *Eur Rev Med Pharmacol Sci* 23: 1652-1660.
15. Zmorzynski S, Szudy-Szczyrek A, Popek-Marciniak S, Korszen-Pilecka I, Wojciewska-Litwin M, et al. (2019) ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple Myeloma. *Front Oncol* 9: 44.
16. Garatachea N, Marin PJ, Lucia A (2013) The ACE DD genotype and D-allele are associated with exceptional longevity: a meta-analysis. *Ageing Res Rev* 12: 1079-1087.
17. Narain Y, Yip A, Murphy T, Brayne C, Easton D, et al. (2000) The ACE gene and Alzheimer's disease susceptibility. *J Med Genet* 37: 695-697.
18. Papadimitriou ID, Lucia A, Pitsiladis YP, Pushkarev VP, Dyatlov DA, et al. (2016) ACTN3 R577X and ACE I/D gene variants influence performance in elite sprinters: a multi-cohort study. *BMC Genomics* 17: 285.
19. Chung CM, Wang RY, Chen JW, Fann CS, Leu HB, et al. (2010) A genome-wide association study identifies new loci for ACE activity: potential implications for response to ACE inhibitor. *Pharmacogenomics J* 10: 537-544.
20. Woo YM, Bae JB, Oh YH, Lee YG, Lee MJ, et al. (2014) Genome-wide methylation profiling of ADPKD identified epigenetically regulated genes associated with renal cyst development. *Hum Genet* 133: 281-297.

- 620 21. Pereira TV, Nunes AC, Rudnicki M, Magistrini R, Albertazzi A, et al. (2006) Influence of ACE I/D
621 gene polymorphism in the progression of renal failure in autosomal dominant polycystic
622 kidney disease: a meta-analysis. *Nephrol Dial Transplant* 21: 3155-3163.
- 623 22. Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis
624 program for the social, behavioral, and biomedical sciences. *Behav Res Methods* 39: 175-
625 191.
- 626 23. Clark MF, Baudouin SV (2006) A systematic review of the quality of genetic association studies in
627 human sepsis. *Intensive Care Med* 32: 1706-1712.
- 628 24. Konoshita T, Miyagi K, Onoe T, Katano K, Mutoh H, et al. (2001) Effect of ACE gene
629 polymorphism on age at renal death in polycystic kidney disease in Japan. *Am J Kidney Dis*
630 37: 113-118.
- 631 25. Lee KB, Kim UK, Lee CC (2000) Association of the ACE gene polymorphism with the progression
632 of autosomal dominant polycystic kidney disease. *J Korean Med Sci* 15: 431-435.
- 633 26. Ramanathan G, Ghosh S, Elumalai R, Periyasamy S, Lakkakula BV (2016) Influence of
634 angiotensin converting enzyme (ACE) gene rs4362 polymorphism on the progression of
635 kidney failure in patients with autosomal dominant polycystic kidney disease (ADPKD). *Indian*
636 *J Med Res* 143: 748-755.
- 637 27. Tripathi G, Dharmani P, Khan F, Sharma RK, Pandirikkal V, et al. (2006) High prevalence of ACE
638 DD genotype among north Indian end stage renal disease patients. *BMC Nephrol* 7: 15.
- 639 28. Tripathi G, Sharma RK, Baburaj VP, Sankhwar SN, Jafar T, et al. (2008) Genetic risk factors for
640 renal failure among north Indian ESRD patients. *Clin Biochem* 41: 525-531.
- 641 29. Uemasu J, Nakaoka A, Kawasaki H, Ishikawa I, Yoshino Y, et al. (1997) Association between
642 angiotensin converting enzyme gene polymorphism and clinical features in autosomal
643 dominant polycystic kidney disease. *Life Sci* 60: 2139-2144.
- 644 30. Baboolal K, Ravine D, Daniels J, Williams N, Holmans P, et al. (1997) Association of the
645 angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in
646 PKD1 adult polycystic kidney disease. *Kidney Int* 52: 607-613.
- 647 31. Buraczynska M, Ksiazek P, Drop A, Zaluska W, Spasiewicz D, et al. (2006) Genetic
648 polymorphisms of the renin-angiotensin system in end-stage renal disease. *Nephrol Dial*
649 *Transplant* 21: 979-983.
- 650 32. Ecdet T, McFann KK, Raynolds MV, Schrier RW (2003) No effect of angiotensin-converting
651 enzyme gene polymorphism on disease progression and left ventricular hypertrophy in
652 autosomal dominant polycystic kidney disease. *Am J Nephrol* 23: 466-470.
- 653 33. Gumprecht J, Zychma MJ, Karasek D, Grzeszczak W (2007) ACE gene I/D polymorphism and the
654 presence of renal failure or hypertension in autosomal dominant polycystic kidney disease
655 (ADPKD). *Nephrol Dial Transplant* 22: 1483.
- 656 34. Lovati E, Richard A, Frey BM, Frey FJ, Ferrari P (2001) Genetic polymorphisms of the renin-
657 angiotensin-aldosterone system in end-stage renal disease. *Kidney Int* 60: 46-54.
- 658 35. Merta M, Reiterova J, Stekrova J, Rysava R, Rihova Z, et al. (2003) Influence of the alpha-
659 adducin and ACE gene polymorphism on the progression of autosomal-dominant polycystic
660 kidney disease. *Kidney Blood Press Res* 26: 42-49.
- 661 36. Perez-Oller L, Torra R, Badenas C, Mila M, Darnell A (1999) Influence of the ACE gene
662 polymorphism in the progression of renal failure in autosomal dominant polycystic kidney
663 disease. *Am J Kidney Dis* 34: 273-278.
- 664 37. Persu A, El-Khattabi O, Messiaen T, Pirson Y, Chauveau D, et al. (2003) Influence of ACE (I/D)
665 and G460W polymorphism of alpha-adducin in autosomal dominant polycystic kidney
666 disease. *Nephrol Dial Transplant* 18: 2032-2038.
- 667 38. Saggari-Malik AK, Afzal AR, Swissman JS, Bland M, Sagnella GA, et al. (2000) Lack of
668 association of ACE/angiotensinogen genotype with renal function in autosomal dominant
669 polycystic kidney disease. *Genet Test* 4: 299-303.
- 670 39. Schiavello T, Burke V, Bogdanova N, Jasik P, Melsom S, et al. (2001) Angiotensin-converting
671 enzyme activity and the ACE Alu polymorphism in autosomal dominant polycystic kidney
672 disease. *Nephrol Dial Transplant* 16: 2323-2327.
- 673 40. van Dijk MA, Breuning MH, Peters DJ, Chang PC (2000) The ACE insertion/deletion
674 polymorphism has no influence on progression of renal function loss in autosomal dominant
675 polycystic kidney disease. *Nephrol Dial Transplant* 15: 836-839.
- 676 41. Wanic-Kossowska M, Posnik B, Kobelski M, Pawliczak E, Pawlaczyk K, et al. (2014) The
677 polymorphism of the ACE gene affects left ventricular hypertrophy and causes disturbances in
678 left ventricular systolic/diastolic function in patients with autosomal dominant polycystic kidney
679 disease. *ScientificWorldJournal* 2014: 707658.

- 680 42. Chen H, Cohen, P, and Chen, S, (2010) How Big is a Big Odds Ratio? Interpreting the
681 Magnitudes of Odds Ratios in Epidemiological Studies. *Communications in Statistics—*
682 *Simulation and Computation* 39: 860–864.
- 683 43. Goodman SN (2005) Introduction to Bayesian methods I: measuring the strength of evidence. *Clin*
684 *Trials* 2: 282-290; discussion 301-284, 364-278.
- 685 44. Goodman SN (1999) Toward evidence-based medical statistics. 2: The Bayes factor. *Ann Intern*
686 *Med* 130: 1005-1013.
- 687 45. Royall R (1997) *Statistical evidence: The likelihood paradigm*. London: Chapman and Hall.
- 688 46. Higgins JP (2008) Commentary: Heterogeneity in meta-analysis should be expected and
689 appropriately quantified. *Int J Epidemiol* 37: 1158-1160.
- 690 47. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-
691 analyses. *Bmj* 327: 557-560.
- 692 48. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. *Stat Med* 21:
693 1539-1558.
- 694 49. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies
695 of disease. *J Natl Cancer Inst* 22: 719-748.
- 696 50. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. *Control Clin Trials* 7: 177-188.
- 697 51. Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical
698 trials. *Stat Med* 7: 889-894.
- 699 52. Ioannidis JP, Trikalinos TA (2007) The appropriateness of asymmetry tests for publication bias in
700 meta-analyses: a large survey. *CMAJ* 176: 1091-1096.
- 701 53. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication
702 bias. *Biometrics* 50: 1088-1101.
- 703 54. Pfeiffer T, Bertram L, Ioannidis JP (2011) Quantifying selective reporting and the Proteus
704 phenomenon for multiple datasets with similar bias. *PLoS One* 6: e18362.
- 705 55. Dumas-Mallet E, Button KS, Boraud T, Gonon F, Munafo MR (2017) Low statistical power in
706 biomedical science: a review of three human research domains. *R Soc Open Sci* 4: 160254.
- 707 56. Crisan D, Carr J (2000) Angiotensin I-converting enzyme: genotype and disease associations. *J*
708 *Mol Diagn* 2: 105-115.
- 709 57. Braliou GG, Grigoriadou AM, Kontou PI, Bagos PG (2014) The role of genetic polymorphisms of
710 the Renin-Angiotensin System in renal diseases: A meta-analysis. *Comput Struct Biotechnol*
711 *J* 10: 1-7.
- 712 58. Zhou TB, Yin SS, Qin YH (2014) Association between angiotensin-converting enzyme
713 insertion/deletion gene polymorphism and end-stage renal disease susceptibility. *J Renin*
714 *Angiotensin Aldosterone Syst* 15: 22-31.
- 715 59. Jardine AG, Padmanabhan N, Connell JM (1998) Angiotensin converting enzyme gene
716 polymorphisms and renal disease. *Curr Opin Nephrol Hypertens* 7: 259-264.
- 717 60. Navis G, van der Kleij FG, de Zeeuw D, de Jong PE (1999) Angiotensin-converting enzyme gene
718 I/D polymorphism and renal disease. *J Mol Med (Berl)* 77: 781-791.
- 719 61. Mizuiri S, Hemmi H, Kumanomidou H, Iwamoto M, Miyagi M, et al. (2001) Angiotensin-converting
720 enzyme (ACE) I/D genotype and renal ACE gene expression. *Kidney Int* 60: 1124-1130.
- 721 62. Davis GK, Millner RW, Roberts DH (2000) Angiotensin converting enzyme (ACE) gene expression
722 in the human left ventricle: effect of ACE gene insertion/deletion polymorphism and left
723 ventricular function. *Eur J Heart Fail* 2: 253-256.
- 724 63. Studer R, Reinecke H, Muller B, Holtz J, Just H, et al. (1994) Increased angiotensin-I converting
725 enzyme gene expression in the failing human heart. Quantification by competitive RNA
726 polymerase chain reaction. *J Clin Invest* 94: 301-310.
- 727 64. Grobe JL, Grobe CL, Beltz TG, Westphal SG, Morgan DA, et al. (2010) The brain Renin-
728 angiotensin system controls divergent efferent mechanisms to regulate fluid and energy
729 balance. *Cell Metab* 12: 431-442.
- 730 65. Turner AJ, Hooper NM (2002) The angiotensin-converting enzyme gene family: genomics and
731 pharmacology. *Trends Pharmacol Sci* 23: 177-183.
- 732 66. Rigat B, Hubert C, Corvol P, Soubrier F (1992) PCR detection of the insertion/deletion
733 polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl
734 carboxypeptidase 1). *Nucleic Acids Res* 20: 1433.
- 735 67. Bell PE, Hossack KF, Gabow PA, Durr JA, Johnson AM, et al. (1988) Hypertension in autosomal
736 dominant polycystic kidney disease. *Kidney Int* 34: 683-690.
- 737 68. Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, et al. (2012) Analysis of baseline
738 parameters in the HALT polycystic kidney disease trials. *Kidney Int* 81: 577-585.

- 739 69. Hian CK, Lee CL, Thomas W (2016) Renin-Angiotensin-Aldosterone System Antagonism and
740 Polycystic Kidney Disease Progression. *Nephron* 134: 59-63.
741 70. Poole C (2001) Low P-values or narrow confidence intervals: which are more durable?
742 *Epidemiology* 12: 291-294.
743 71. Moore JH, Williams SM (2002) New strategies for identifying gene-gene interactions in
744 hypertension. *Ann Med* 34: 88-95.
745 72. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC (2006) ACE
746 polymorphisms. *Circ Res* 98: 1123-1133.

747
748
749

Author contributions

Conceptualization: NP, PT
Data curation: NP, PT and YP
Formal analysis: NP, PT and YP
Investigation: NP, PT
Methodology: NP, PT and YP
Project administration: NP, PT
Resources: PT, NP and AT
Software: NP, PT
Supervision: NP
Validation: NP, PT, YP and AT
Visualization: NP, PT and YP
Writing – original draft: NP, PT
Writing – review & editing: NP, PT, YP and AT

750

Data availability statement

751 All relevant data are within the paper and its Supporting information files

752

753

Funding

754 This research did not receive any specific grant from funding agencies in the public, commercial, or
755 not-for-profit sectors

756

757

Competing interests

758 The authors have no conflicts of interest to declare

759


760


Supporting information


761	S1 List	Excluded articles	DOCX
762	S1 Table	Quantitative	DOCX
763	S2 Table	PRISMA checklist	DOCX
764	S3 Table	Genetic checklist	DOCX
765	S5 Data	Raw data code	XLS

March 12, 2019

“angiotensin converting enzyme”, *“ACE”*, *“ADPKD”*, *“autosomal dominant polycystic kidney disease”* and *“polymorphism”*







medRxiv preprint doi: <https://doi.org/10.1101/1902048>; this version posted August 9, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

